S. John Weroha

5.2k total citations
71 papers, 1.5k citations indexed

About

S. John Weroha is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, S. John Weroha has authored 71 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 33 papers in Oncology and 30 papers in Reproductive Medicine. Recurrent topics in S. John Weroha's work include Ovarian cancer diagnosis and treatment (30 papers), PARP inhibition in cancer therapy (10 papers) and Growth Hormone and Insulin-like Growth Factors (7 papers). S. John Weroha is often cited by papers focused on Ovarian cancer diagnosis and treatment (30 papers), PARP inhibition in cancer therapy (10 papers) and Growth Hormone and Insulin-like Growth Factors (7 papers). S. John Weroha collaborates with scholars based in United States, Italy and Spain. S. John Weroha's co-authors include Paul Haluska, Xiaonan Hou, Sara Antonia Li, Jonathan J. Li, Wilma L. Lingle, Ann L. Oberg, Marc A. Becker, Jeffrey L. Salisbury, Sean C. Harrington and Ossama Tawfik and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

S. John Weroha

66 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. John Weroha United States 21 741 610 368 276 230 71 1.5k
Joseph Kwong Hong Kong 32 1.6k 2.2× 803 1.3× 757 2.1× 313 1.1× 170 0.7× 56 2.8k
Nameer B. Kirma United States 22 593 0.8× 402 0.7× 286 0.8× 190 0.7× 357 1.6× 63 1.4k
Gloria Peiró Spain 26 737 1.0× 644 1.1× 519 1.4× 75 0.3× 140 0.6× 64 1.7k
Jean S. Beebe United States 19 636 0.9× 314 0.5× 142 0.4× 65 0.2× 312 1.4× 39 1.7k
Nathalie Boulle France 21 723 1.0× 334 0.5× 367 1.0× 57 0.2× 433 1.9× 45 1.5k
Hongling Peng China 24 885 1.2× 404 0.7× 470 1.3× 181 0.7× 157 0.7× 117 1.7k
M. J. Birrer United States 14 947 1.3× 537 0.9× 337 0.9× 229 0.8× 191 0.8× 24 1.5k
Hongzhen Li United States 20 712 1.0× 639 1.0× 267 0.7× 31 0.1× 163 0.7× 61 1.6k

Countries citing papers authored by S. John Weroha

Since Specialization
Citations

This map shows the geographic impact of S. John Weroha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. John Weroha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. John Weroha more than expected).

Fields of papers citing papers by S. John Weroha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. John Weroha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. John Weroha. The network helps show where S. John Weroha may publish in the future.

Co-authorship network of co-authors of S. John Weroha

This figure shows the co-authorship network connecting the top 25 collaborators of S. John Weroha. A scholar is included among the top collaborators of S. John Weroha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. John Weroha. S. John Weroha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kong, Xiangyi, Hongming Song, Li Wang, et al.. (2025). Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition. Molecular & Cellular Proteomics. 24(12). 101316–101316.
2.
3.
Dinoi, Giorgia, Simone Garzon, Amy L. Weaver, et al.. (2024). How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer. International Journal of Gynecological Cancer. 34(9). 1389–1398.
4.
Ismail, Wazim Mohammed, Amelia Mazzone, Jenna Fernandez, et al.. (2023). Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling. Genes. 14(6). 1245–1245. 4 indexed citations
5.
Shetty, Mihir, Andrew C. Nelson, Britt Erickson, et al.. (2022). GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors. Cancer Research Communications. 2(8). 784–794. 8 indexed citations
6.
Tang, Xiaojia, Jianning Song, Upasana Ray, et al.. (2022). DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model. NAR Cancer. 4(3). zcac022–zcac022. 1 indexed citations
7.
Kurnit, Katherine C., Ricardo R. Lastra, S. John Weroha, et al.. (2022). High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecologic Oncology Reports. 41. 100987–100987. 2 indexed citations
8.
9.
Yoo, Ki Hyun, Mohammad Mamun Ur Rashid, Chang Hoon Cho, et al.. (2021). Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Research. 81(13). 3727–3737. 36 indexed citations
10.
Kanakkanthara, Arun, Xiaonan Hou, Valentina Zanfagnin, et al.. (2021). Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research. 82(2). 307–319. 14 indexed citations
11.
Barrett, Michael T., Faye R. Harris, Ryan W. Feathers, et al.. (2021). Combination targeted treatment may enhance antitumor activity in ERBB3 amplified high-grade serous endometrial cancer cells resistant to single agent targeted therapy. Gynecologic Oncology. 162. S114–S115.
12.
Serebrenik, Artur A., Prokopios P. Argyris, Matthew C. Jarvis, et al.. (2020). The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research. 26(13). 3397–3407. 48 indexed citations
13.
Dadgar, Neda, Alan M. Gonzalez‐Suarez, Pouria Fattahi, et al.. (2020). A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. Microsystems & Nanoengineering. 6(1). 76 indexed citations
14.
Mehner, Christine, Erin Miller, Alexandra Hockla, et al.. (2020). Targeting an autocrine IL-6–SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene. 39(42). 6606–6618. 17 indexed citations
15.
Kanakkanthara, Arun, Kiran Kurmi, Xiaonan Hou, et al.. (2019). BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research. 79(23). 5920–5929. 45 indexed citations
16.
Bartlett, David J., Daniel S. Childs, Carmen Radecki Breitkopf, et al.. (2018). Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. American Journal of Hospice and Palliative Medicine®. 35(11). 1384–1389. 2 indexed citations
17.
Hurley, Rachel M., Ksenija Nesic, Olga Kondrashova, et al.. (2018). Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance. 78(13). 1 indexed citations
18.
Yang, Yinhui, Dejie Wang, Jian An, et al.. (2017). Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Research. 77(23). 6524–6537. 47 indexed citations
19.
Becker, Marc A., Sean C. Harrington, James Krempski, et al.. (2013). Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth. Molecular Cancer Therapeutics. 12(12). 2909–2916. 7 indexed citations
20.
Becker, Marc A., Xiaonan Hou, Sean C. Harrington, et al.. (2012). IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors. Clinical Cancer Research. 18(6). 1808–1817. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph Kwong Breakdown of academic impact, for papers by Nameer B. Kirma Breakdown of academic impact, for papers by Gloria Peiró Breakdown of academic impact, for papers by Jean S. Beebe Breakdown of academic impact, for papers by Nathalie Boulle Breakdown of academic impact, for papers by Hongling Peng Breakdown of academic impact, for papers by M. J. Birrer Breakdown of academic impact, for papers by Hongzhen Li
Rankless by CCL
2026